Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

The Latest Advances and Guidance in Nonmetastatic Castration-Resistant Prostate Cancer

In this podcast episode, listen to Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, as they discuss clinical implications of the latest data from ASCO 2021 on using androgen receptor–directed therapy for the treatment and management of patients with nonmetastatic castration-resistant prostate cancer.
Karim Fizazi, MD, PhD
Alicia K. Morgans, MD, MPH
Released: July 30, 2021

Acknowledgements

Supported by an educational grant from
Bayer HealthCare

Information on this Educational Activity

Faculty

Karim Fizazi, MD, PhD

Full Professor
Cancer Medicine
Gustave Roussey
Villejuif, France

Karim Fizazi, MD, PhD, has disclosed that he has received consulting fees from AAA, Amgen, Astellas, AstraZeneca, Bayer, Clovis, CureVac, ESSA, Genentch, Janssen, MSD, Orion, and Sanofi.
Alicia K. Morgans, MD, MPH

Genitourinary Medical Oncologist
Dana-Farber Cancer Institute
Boston, Massachusetts

Alicia K. Morgans, MD, PhD, has disclosed that she has received funds for research support from Bayer, Dendreon, Myovant, Sanofi, and Seattle Genetics and consulting fees from AAA, AstraZeneca, Astellas, Bayer, Blue Earth, Clovis, Dendreon, Exelixis, Janssen, Myovant, Myriad, Novartis, Pfizer, Sanofi and Seattle Genetics.

Program Medium

This program has been made available online.

Related Content

Virtual presentation by Shannon N. Westin, MD, MPH, on improving health equity for patients with endometrial cancer, from Clinical Care Options (CCO)

Shannon N. Westin, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Global perspective of key studies presented at ASCO, EHA, ICML 2021 from an international expert in CLL from Clinical Care Options (CCO)

George Follows, BM, BCh, PhD Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, from CCO

Julie Brahmer, MD, MSc person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Download these slides for an overview of the evolving immunotherapy landscape for early-stage resectable and stage III unresectable NSCLC, from CCO

person default Jarushka Naidoo, MB BCH BAO, MHS Released: September 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue